AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Triple Negative Breast Cancer in 2026: ADCs Move to the Front, Immunotherapy Stays Central, and Biomarkers Still Lag Behind
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
Triple Negative Breast Cancer in 2026: ADCs Move to the Front, Immunotherapy Stays Central, and Biomarkers Still Lag Behind
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
Triple Negative Breast Cancer in 2026: ADCs Move to the Front, Immunotherapy Stays Central, and Biomarkers Still Lag Behind
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.
The Venetoclax Revolution in AML, and Its Limits in MDS: What the PARADIGM and VERONA Trials Mean for Practice
By By Bart L. Scott, MD
The PARADIGM and VERONA trials tell two very different stories about venetoclax in myeloid malignancies—a promising shift in AML treatment and a sobering setback in MDS. A leading expert breaks down both.
The Venetoclax Revolution in AML, and Its Limits in MDS: What the PARADIGM and VERONA Trials Mean for Practice
By By Bart L. Scott, MD
The PARADIGM and VERONA trials tell two very different stories about venetoclax in myeloid malignancies—a promising shift in AML treatment and a sobering setback in MDS. A leading expert breaks down both.
The Venetoclax Revolution in AML, and Its Limits in MDS: What the PARADIGM and VERONA Trials Mean for Practice
By By Bart L. Scott, MD
The PARADIGM and VERONA trials tell two very different stories about venetoclax in myeloid malignancies—a promising shift in AML treatment and a sobering setback in MDS. A leading expert breaks down both.
Belzutifan in 2026: Three Phase 3 Trials, Two Likely Approvals, and One Negative Surprise
By Scott Tykodi, MD, PhD
Three Phase 3 trials of belzutifan in clear cell RCC reported in 2026: two positive results poised for FDA approval, and one frontline surprise that leaves the current standard of care intact.
Belzutifan in 2026: Three Phase 3 Trials, Two Likely Approvals, and One Negative Surprise
By Scott Tykodi, MD, PhD
Three Phase 3 trials of belzutifan in clear cell RCC reported in 2026: two positive results poised for FDA approval, and one frontline surprise that leaves the current standard of care intact.
Belzutifan in 2026: Three Phase 3 Trials, Two Likely Approvals, and One Negative Surprise
By Scott Tykodi, MD, PhD
Three Phase 3 trials of belzutifan in clear cell RCC reported in 2026: two positive results poised for FDA approval, and one frontline surprise that leaves the current standard of care intact.
Ten Years of CAR-T, and Ten More to Come: A Measured Look at What the Next Decade Will Bring
By Sattva S. Neelapu, MD
A CAR-T cell therapy pioneer reflects on a decade of progress and offers measured predictions for 2036—from frontline use and dual-target CARs to in vivo delivery and beyond oncology.
Ten Years of CAR-T, and Ten More to Come: A Measured Look at What the Next Decade Will Bring
By Sattva S. Neelapu, MD
A CAR-T cell therapy pioneer reflects on a decade of progress and offers measured predictions for 2036—from frontline use and dual-target CARs to in vivo delivery and beyond oncology.
Ten Years of CAR-T, and Ten More to Come: A Measured Look at What the Next Decade Will Bring
By Sattva S. Neelapu, MD
A CAR-T cell therapy pioneer reflects on a decade of progress and offers measured predictions for 2036—from frontline use and dual-target CARs to in vivo delivery and beyond oncology.
CAR-T Cell Therapy in Follicular Lymphoma and CLL: Identifying the High-Risk Patients Who Need It Most
By Bradley W. Christensen, MD
Expert commentary on CAR-T therapy for follicular lymphoma and CLL, focusing on POD24 patients, FLIPI-2 risk, bispecific antibodies, and emerging treatment strategies.
CAR-T Cell Therapy in Follicular Lymphoma and CLL: Identifying the High-Risk Patients Who Need It Most
By Bradley W. Christensen, MD
Expert commentary on CAR-T therapy for follicular lymphoma and CLL, focusing on POD24 patients, FLIPI-2 risk, bispecific antibodies, and emerging treatment strategies.
CAR-T Cell Therapy in Follicular Lymphoma and CLL: Identifying the High-Risk Patients Who Need It Most
By Bradley W. Christensen, MD
Expert commentary on CAR-T therapy for follicular lymphoma and CLL, focusing on POD24 patients, FLIPI-2 risk, bispecific antibodies, and emerging treatment strategies.
The Hidden Barrier to Precision Oncology: How Insurance Policies Delay Access to Genomic Testing
By Ira Klein, MBA, MD, FACP
Dr. Ira Klein explores how outdated insurance policies, prior authorization burdens, and administrative barriers delay equitable access to precision oncology testing.
The Hidden Barrier to Precision Oncology: How Insurance Policies Delay Access to Genomic Testing
By Ira Klein, MBA, MD, FACP
Dr. Ira Klein explores how outdated insurance policies, prior authorization burdens, and administrative barriers delay equitable access to precision oncology testing.
The Hidden Barrier to Precision Oncology: How Insurance Policies Delay Access to Genomic Testing
By Ira Klein, MBA, MD, FACP
Dr. Ira Klein explores how outdated insurance policies, prior authorization burdens, and administrative barriers delay equitable access to precision oncology testing.
AI in Breast Diagnostics: Why What We Do With the Tool Matters More Than the Tool Itself
By Benjamin O. Anderson, MD, FACS
Dr. Benjamin O. Anderson explores the promise and limitations of AI in breast diagnostics, emphasizing that patient navigation, infrastructure, and access to care matter more than technology alone.
AI in Breast Diagnostics: Why What We Do With the Tool Matters More Than the Tool Itself
By Benjamin O. Anderson, MD, FACS
Dr. Benjamin O. Anderson explores the promise and limitations of AI in breast diagnostics, emphasizing that patient navigation, infrastructure, and access to care matter more than technology alone.
AI in Breast Diagnostics: Why What We Do With the Tool Matters More Than the Tool Itself
By Benjamin O. Anderson, MD, FACS
Dr. Benjamin O. Anderson explores the promise and limitations of AI in breast diagnostics, emphasizing that patient navigation, infrastructure, and access to care matter more than technology alone.
The Immunotherapy Landscape in Colorectal Cancer: Where We Stand and Where We're Headed
By Ibrahim Halil Sahin, MD
Expert commentary on the evolving role of immunotherapy in colorectal cancer, including MSI-H breakthroughs, MSS challenges, biomarker-driven treatment, and emerging clinical trial strategies.
The Immunotherapy Landscape in Colorectal Cancer: Where We Stand and Where We're Headed
By Ibrahim Halil Sahin, MD
Expert commentary on the evolving role of immunotherapy in colorectal cancer, including MSI-H breakthroughs, MSS challenges, biomarker-driven treatment, and emerging clinical trial strategies.
The Immunotherapy Landscape in Colorectal Cancer: Where We Stand and Where We're Headed
By Ibrahim Halil Sahin, MD
Expert commentary on the evolving role of immunotherapy in colorectal cancer, including MSI-H breakthroughs, MSS challenges, biomarker-driven treatment, and emerging clinical trial strategies.
CAR-T Cell Therapy in Aggressive Lymphoma: Navigating Standard-of-Care Products, Sequencing Strategies, and the Road to Frontline Use
By Elif Yilmaz, MD
Expert commentary on CAR-T cell therapy in aggressive lymphoma, including DLBCL and mantle cell lymphoma, with insights on product selection, toxicity, sequencing strategies, and frontline applications.
CAR-T Cell Therapy in Aggressive Lymphoma: Navigating Standard-of-Care Products, Sequencing Strategies, and the Road to Frontline Use
By Elif Yilmaz, MD
Expert commentary on CAR-T cell therapy in aggressive lymphoma, including DLBCL and mantle cell lymphoma, with insights on product selection, toxicity, sequencing strategies, and frontline applications.
CAR-T Cell Therapy in Aggressive Lymphoma: Navigating Standard-of-Care Products, Sequencing Strategies, and the Road to Frontline Use
By Elif Yilmaz, MD
Expert commentary on CAR-T cell therapy in aggressive lymphoma, including DLBCL and mantle cell lymphoma, with insights on product selection, toxicity, sequencing strategies, and frontline applications.